Showing results (41-50 of 72) with videos related to

Sort By:
Pageof 8
Clinical and Translational Science|February 12, 2024
Population pharmacokinetics and exposure-response analyses for efficacy and safety of upadacitinib in patients with axial spondyloarthritisSumit Bhatnagar, Doerthe Eckert, Sven Stodtmann, et al.
The AAPS Journal|October 27, 2019
Development of In Vitro-In Vivo Correlation for Upadacitinib Extended-Release Tablet FormulationMohamed-Eslam F Mohamed, Sheryl Trueman, Ahmed A Othman, et al.
Clinical Pharmacology in Drug Development|July 11, 2020
Characterization of the Effect of Upadacitinib on the Pharmacokinetics of Bupropion, a Sensitive Cytochrome P450 2B6 Probe SubstrateMohamed-Eslam F Mohamed, Mukul Minocha, Sheryl Trueman, et al.
Alimentary Pharmacology & Therapeutics|September 28, 2022
Prevalence and clinical characteristics of patients with metabolic dysfunction-associated fatty liver disease with hepatitis C virus infection-a population-based studyDina Attia, Shereen Abdel Alem, Wafaa El-Akel, et al.
Clinical Pharmacokinetics|June 9, 2016
Pharmacokinetics, Safety and Tolerability of ABT-494, a Novel Selective JAK 1 Inhibitor, in Healthy Volunteers and Subjects with Rheumatoid ArthritisMohamed-Eslam F Mohamed, Heidi S Camp, Ping Jiang, et al.
Clinical Pharmacology and Therapeutics|September 30, 2024
Extrapolation of Upadacitinib Efficacy in Juvenile Idiopathic Arthritis Leveraging Pharmacokinetics, Exposure-Response Models, and Real-World Patient DataYuli Qian, Louisa Schlachter, Doerthe Eckert, et al.
Clinical Pharmacology and Therapeutics|October 15, 2019
Exposure-Response Analyses of Upadacitinib Efficacy and Safety in Phase II and III Studies to Support Benefit-Risk Assessment in Rheumatoid ArthritisAhmed Nader, Mohamed-Eslam F Mohamed, Insa Winzenborg, et al.
South Asian Journal of Cancer|May 9, 2024
Changes in the Etiologies of Liver Cancer in Upper Egypt over a Decade from 2010 to 2020: A Single Tertiary Care Center StudyYasser Fouad, Yasmine Gaber, Shereen Abdel Alem, et al.
Clinical and Translational Science|October 13, 2020
Coproporphyrin I Can Serve as an Endogenous Biomarker for OATP1B1 Inhibition: Assessment Using a Glecaprevir/Pibrentasvir Clinical StudyHari V Kalluri, Ryota Kikuchi, Sheryl Coppola, et al.
Clinical Pharmacology in Drug Development|January 17, 2024
Cedirogant Population Pharmacokinetics and Pharmacodynamic Analyses of Interleukin-17A Inhibition in Two Phase 1 Studies in Healthy Participants and Participants with Moderate to Severe PsoriasisCorinna S Maier, Doerthe Eckert, F Stephen Laroux, et al.
Pageof 8